Intravenous (IV) Psychedelic Therapy
What is Intravenous (IV) Psychedelic Therapy?
Intravenous (IV) psychedelic therapy is primarily delivered as an anesthetic medication that is also used for treatment-resistant mood disorders. Numerous clinical trials have demonstrated that psychedelic therapy has rapid and robust antidepressant effects in individuals who continue to suffer despite trying numerous antidepressant medications and psychotherapy.
Request A ReferralWhy Choose Intravenous (IV) Psychedelic Therapy with Braxia Health?
Fast-Acting Relief
IV Psychedelic Therapy works quickly, often providing noticeable improvement in mood and symptoms within hours or days—especially for individuals who haven’t responded to traditional treatments.
Personalized & Controlled Care
Our in-clinic treatments follow rigorous protocols developed by the top psychiatrists in Canada. Each patient’s journey is tailored to their specific circumstances and closely monitored over time.
Proven for Treatment-Resistant Conditions
IV Psychedelic Therapy has strong clinical evidence supporting its use for treatment-resistant depression, anxiety, PTSD, and chronic mood disorders when other therapies have not worked.
Physician Resources: Published Research
Frequently Asked Questions
Several drugs have recently emerged as a rapid-acting and effective treatment for mood disorders when traditional medications are ineffective. The treatments are administered under strictly controlled conditions by medical professionals.
At the Braxia Health we treat Major Depressive Disorder, and Bipolar Depression. Individuals Post Traumatic Stress Disorder (PTSD) or Obsessive-Compulsive Disorder (OCD) will be considered on a case-by-case basis.
The long-term efficacies in individuals who have responded to this treatment modality are not yet fully known. Emerging evidence indicates that some individuals remain well for several months. Undoubtedly, there will be some individuals who remain well for longer periods of time. It’s also known that other individuals will require booster sessions to maintain their feelings of wellness. The booster sessions are typically administered approximately once per month, depending on the chosen molecule.
This depends on the drug and will be assessed by our physicians during the intake process. Generally:
- Any individual who has a primary diagnosis is anything other than MDD or BD. As noted above, individual consideration will be given on a case-by-case basis for adults with either PTSD or OCD.
- Individuals who meet DSM-5 criteria for a substance use and or alcohol use disorder
- Any individual who has met DSM-5 criteria for a Substance Use Disorder and/or alcohol use disorder in the past 3 months.
- All individuals who use illicit substances (but do not meet criteria for Substance Use Disorder according to the DSM-5 criteria) must refrain from using substances for a minimum of one month prior to their first infusion at Braxia Health.
- Individuals who are experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent)
- Individuals with a dementing disorder (e.g., Alzheimer’s disease)
- Individuals who are unable to provide written consent to the treatment
- Individuals who are unable to adhere to the protocol in its totality (i.e., remain in the clinic post infusion for a minimum of 20 minutes or as advised by the medical team for observation).
- Individuals who are unable to identify a person to ensure their safe transport to home post infusion
- Individuals with symptomatic traumatic brain injury
- Uncontrolled medical disorders (i.e., uncontrolled and/or insufficiently treated hypertension, allergies to the drug and/or previous intolerability of the drug)
- Pregnancy
- Medical contraindications to the molecule (e.g. epilepsy)
- Patients that are over 275 lbs.
- Patients who do not adhere to Braxia Health protocol with respect to chaperoning during the visit and post-discharge
- Individuals will be ineligible for treatment if they are not a Canadian resident
- Any patient who does not have a community MRP will not be accepted for assessment or any procedure at Braxia Health.
- Any individual who exhibits aggressive or intimidating behaviour towards Braxia Health staff or other patients will not be eligible for treatment at Braxia Health.
- Any patient who does not adhere to all pre-procedure recommendations (e.g., food fasting) is not eligible for treatment at Braxia Health.
- Patients feeling acutely unwell for any reason (e.g. symptoms of infection) and/or have come into direct contact with someone acutely ill from a transmissible infection.
Psychedelic Therapy for Rapid Mental Health Relief
Psychedelic Assisted Therapy is an innovative approach that combines guided psychotherapy with carefully supervised psychedelic treatment. This method helps individuals gain deeper emotional insights, process unresolved experiences, and support meaningful mental health improvements. Conducted in a safe and professional environment, the therapy aims to promote lasting emotional healing, clarity, and overall well-being. Note that not all patients benefit from this treatment.
- Fast-Acting Relief: Psychedelic Therapy can reduce symptoms within hours or days, rather than weeks.
- Clinically Supported Treatment: Backed by research for treatment-resistant mood disorders.
- Personalized & Controlled Care: Each session is carefully tailored and monitored by medical professionals for safety and effectiveness.
- Supervised Medical Environment: Administered in a safe, controlled clinical setting to ensure patient comfort and care.
Psychedelic Therapy for Major Depression, Bipolar Disorder & PTSD
Psychedelic therapy is a medically-supervised treatment designed for individuals experiencing mood disorders, especially when traditional treatments have not provided sufficient relief. It works by targeting different brain pathways than conventional antidepressants, helping improve symptoms related to mood disorders. Many patients experience a reduction in symptoms within a few treatments while other patients require additional treatments to benefit from psychedelic therapy.
